Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Rocket Pharmaceuticals Inc (RCKT) COM USD0.01

Sell:$55.21 Buy:$55.30 Change: $3.07 (5.26%)
Market closed |  Prices as at close on 15 January 2021 | Switch to live prices |
Sell:$55.21
Buy:$55.30
Change: $3.07 (5.26%)
Market closed |  Prices as at close on 15 January 2021 | Switch to live prices |
Sell:$55.21
Buy:$55.30
Change: $3.07 (5.26%)
Market closed |  Prices as at close on 15 January 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is focused on developing gene therapy treatment options for rare, devastating diseases. The Company’s multi-platform development approach applies the well-established lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms. The Company’s lead clinical program is a LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a genetic disease that leads to bone marrow failure and potentially cancer. Its additional pipeline programs for bone marrow-derived disorders are for Pyruvate Kinase Deficiency (PKD), Leukocyte Adhesion Deficiency-I (LAD-I) and Infantile Malignant Osteopetrosis (IMO). The Company is also developing an AAV-based gene therapy program for pediatric heart failure indication, Danon disease.

Contact details

Address:
350 5th Ave Ste 7530
NEW YORK
10118-7501
United States
Telephone:
+1 (646) 4409100
Website:
https://www.rocketpharma.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
RCKT
ISIN:
US77313F1066
Market cap:
$3.33 billion
Shares in issue:
60.54 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Roderick Wong
    Chairman of the Board
  • Gaurav Shah
    President, Chief Executive Officer, Director
  • Carlos Garcia-Parada
    Chief Financial Officer
  • Kinnari Patel
    Chief Operating Officer and Head of Development
  • Kamran Alam
    Senior Vice President - Finance
  • John Militello
    Principal Accounting Officer, Vice President - Finance, Senior Controller, Treasurer
  • Jonathan Schwartz
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.